Randomized, controlled phase II trial of exemestane compared with medroxyprogesterone after nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer.

Randomized Controlled ◽

Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement

Current Oncology ◽

10.3747/co.20.1316 ◽

2013 ◽

Vol 20 (1) ◽

Cited By ~ 14

Author(s):

K.I. Pritchard ◽

K.A. Gelmon ◽

D. Rayson ◽

L. Provencher ◽

Marc Webster ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Consensus Statement ◽

Inhibitor Therapy ◽

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(09)79195-7 ◽

2009 ◽

Vol 20 (1) ◽

pp. 94-95

Author(s):

Y.H. Chia ◽

C.X. Ma

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Controlled Trial ◽

Inhibitor Therapy ◽

Double Blind ◽

Abstract P3-11-02: A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study)

10.1158/1538-7445.sabcs17-p3-11-02 ◽

2018 ◽

Author(s):

R Nishimura ◽

Y Yamamoto ◽

K Narui ◽

Y Kijima ◽

Y Hozumi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Randomized Phase Ii

Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First‐Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor‐Positive/HER2‐Negative Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0021 ◽

2014 ◽

Vol 19 (4) ◽

pp. 348-349 ◽

Cited By ~ 14

Author(s):

Beverly Moy ◽

Patrick Neven ◽

Fabienne Lebrun ◽

Meritxell Bellet ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Locally Advanced ◽

First Line ◽

Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor‐Positive/HER2‐Negative Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0022 ◽

2014 ◽

Vol 19 (4) ◽

pp. 346-347 ◽

Cited By ~ 8

Author(s):

Beverly Moy ◽

Patrick Neven ◽

Fabienne Lebrun ◽

Meritxell Bellet ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Locally Advanced ◽

Previously Treated

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

European Journal of Cancer ◽

10.1016/j.ejca.2015.10.012 ◽

2016 ◽

Vol 53 ◽

pp. 144-154 ◽

Cited By ~ 19

Author(s):

Konstantinos Tryfonidis ◽

Gul Basaran ◽

Jan Bogaerts ◽

Marc Debled ◽

Luc Dirix ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

European Organisation ◽

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

10.1158/0008-5472.sabcs11-pd01-01 ◽

2011 ◽

Cited By ~ 6

Author(s):

GL Wright ◽

J Blum ◽

LK Krekow ◽

KJ McIntyre ◽

ST Wilks ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Previously Treated

LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2247 ◽

2020 ◽

Vol 31 ◽

pp. S1151

Author(s):

J. Albanell ◽

M.T.M. Martinez ◽

M. Ramos ◽

M.O.' Connor ◽

L. De la Cruz-Merino ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial

Annals of Oncology ◽

10.1093/annonc/mdu015 ◽

2014 ◽

Vol 25 (4) ◽

pp. 831-836 ◽

Cited By ~ 32

Author(s):

J. Bines ◽

R. Dienstmann ◽

R.M. Obadia ◽

L.G.P. Branco ◽

D.C. Quintella ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Breast ◽

Megestrol Acetate

Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)

10.1158/1538-7445.sabcs19-p5-13-02 ◽

2020 ◽

Author(s):

Maysa M Abu-Khalaf ◽

Kimberly Aderhold ◽

Michal Marczyk ◽

Gina Chung ◽

Erin Hofstatter ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Mtor Inhibitor ◽

Recurrence Score ◽

Oncotype Dx ◽

Oncotype Dx Recurrence Score